TY - JOUR AU - Vermorken, J. B. AU - Specenier, P. PY - 2010 DA - 2010// TI - Optimal treatment for recurrent/metastatic head and neck cancer JO - Ann Oncol VL - 21 ID - Vermorken2010 ER - TY - STD TI - National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancer. Version 2.2014. http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed 24 Nov 2014. UR - http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf ID - ref2 ER - TY - JOUR AU - Vermorken, J. B. AU - Mesia, R. AU - Rivera, F. AU - Remenar, E. AU - Kawecki, A. AU - Rottey, S. PY - 2008 DA - 2008// TI - Platinum-based chemotherapy plus cetuximab in head and neck cancer JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0802656 DO - 10.1056/NEJMoa0802656 ID - Vermorken2008 ER - TY - JOUR AU - Burtness, B. AU - Goldwasser, M. A. AU - Flood, W. AU - Mattar, B. AU - Forastiere, A. A. PY - 2005 DA - 2005// TI - Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.02.4646 DO - 10.1200/JCO.2005.02.4646 ID - Burtness2005 ER - TY - STD TI - Erbitux Prescribing Information. Revised August 2013. Branchburg, NJ: ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company. http://packageinserts.bms.com/pi/pi_erbitux.pdf. Accessed 11 Nov 2014. UR - http://www.packageinserts.bms.com/pi/pi_erbitux.pdf ID - ref5 ER - TY - STD TI - Erbitux Summary of Product Characteristics. Revised August 2014. Darmstadt, Germany: Merck KGaA. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000558/WC500029119.pdf. Accessed 26 Nov 2014. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000558/WC500029119.pdf ID - ref6 ER - TY - STD TI - A Study in Head and Neck Cancer. ClinicalTrials.gov study record. http://clinicaltrials.gov/show/NCT01081041. Accessed 27 Nov 2014. UR - http://clinicaltrials.gov/show/NCT01081041 ID - ref7 ER - TY - STD TI - Platinol [product information]. Bristol-Myers Squibb Company 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s080lbl.pdf. Accessed 11 Nov 2014. UR - http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s080lbl.pdf ID - ref8 ER - TY - STD TI - Carboplatin FDA Professional Drug Information. http://www.drugs.com/pro/carboplatin.html. Accessed 14 Nov 2016. UR - http://www.drugs.com/pro/carboplatin.html ID - ref9 ER - TY - STD TI - Adrucil (Fluorouracil) Injection. TEVA Parenteral Medicines, Inc. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0794add-67a7-4308-93e9-f889472716cc. Accessed 11 Nov 2014. UR - http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0794add-67a7-4308-93e9-f889472716cc ID - ref10 ER - TY - JOUR AU - Bourhis, J. AU - Rivera, F. AU - Mesia, R. AU - Awada, A. AU - Geoffrois, L. AU - Borel, C. PY - 2006 DA - 2006// TI - Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.04.3547 DO - 10.1200/JCO.2005.04.3547 ID - Bourhis2006 ER -